betahistine has been researched along with Body Weight in 4 studies
Betahistine: A histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.
betahistine : An aminoalkylpyridine that is pyridine substituted by a 2-(methylamino)ethyl group at position 2. It acts as a histamine agonist and a vasodilator, and is thought to improve the microcirculation of the labyrinth, resulting in reduced endolymphatic pressure. It is used (generally as the hydrochloride or mesylate salt) to reduce the symptoms of vertigo, tinnitus, and hearing loss associated with Meniere's disease.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "), was coadministered with olanzapine (10 mg/day) in three first-episode schizophrenia patients for 6 weeks." | 9.11 | The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. ( Levi, A; Pashinian, A; Poyurovsky, M; Weizman, A; Weizman, R, 2005) |
| "Chemerin is an anorexigenic adipokine, whose dysregulation is implicated in diet, and olanzapine-induced obesity through a histamine/AMPK axis in the ARC." | 8.02 | Crosstalk of hypothalamic chemerin, histamine, and AMPK in diet-and olanzapine-induced obesity in rats. ( Abdelmonsif, DA; Hassaan, PS; Ismail, CA; Mostafa, DK; Samy, DM, 2021) |
| "Betahistine therapy was also accompanied by progressive, significant improvements in both HADS-A and HADS-D scores (p < 0." | 6.75 | Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study. ( Benecke, H; Bin Sidek, D; D, K; Pérez-Garrigues, H; Sondag, E; Theeuwes, A; Uloziene, I, 2010) |
| "These results suggest that betahistine may potentially be a useful adjunctive drug for decreasing weight gain in patients treated with antipsychotics that are potent histamine antagonists, such as olanzapine or clozapine, but may not be useful for this purpose in patients on other antipsychotic medications." | 5.27 | Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. ( Davis, JM; Jin, H; Jing, Z; Maayan, L; Meyers, J; Sershen, H; Smith, RC; Szabo, V; Wu, R; Youssef, M; Zhao, J, 2018) |
| "), was coadministered with olanzapine (10 mg/day) in three first-episode schizophrenia patients for 6 weeks." | 5.11 | The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. ( Levi, A; Pashinian, A; Poyurovsky, M; Weizman, A; Weizman, R, 2005) |
| "Chemerin is an anorexigenic adipokine, whose dysregulation is implicated in diet, and olanzapine-induced obesity through a histamine/AMPK axis in the ARC." | 4.02 | Crosstalk of hypothalamic chemerin, histamine, and AMPK in diet-and olanzapine-induced obesity in rats. ( Abdelmonsif, DA; Hassaan, PS; Ismail, CA; Mostafa, DK; Samy, DM, 2021) |
| "Betahistine therapy was also accompanied by progressive, significant improvements in both HADS-A and HADS-D scores (p < 0." | 2.75 | Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study. ( Benecke, H; Bin Sidek, D; D, K; Pérez-Garrigues, H; Sondag, E; Theeuwes, A; Uloziene, I, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Samy, DM | 1 |
| Mostafa, DK | 1 |
| Abdelmonsif, DA | 1 |
| Ismail, CA | 1 |
| Hassaan, PS | 1 |
| Smith, RC | 1 |
| Maayan, L | 1 |
| Wu, R | 1 |
| Youssef, M | 1 |
| Jing, Z | 1 |
| Sershen, H | 1 |
| Szabo, V | 1 |
| Meyers, J | 1 |
| Jin, H | 1 |
| Zhao, J | 1 |
| Davis, JM | 1 |
| Benecke, H | 1 |
| Pérez-Garrigues, H | 1 |
| Bin Sidek, D | 1 |
| Uloziene, I | 1 |
| D, K | 1 |
| Sondag, E | 1 |
| Theeuwes, A | 1 |
| Poyurovsky, M | 1 |
| Pashinian, A | 1 |
| Levi, A | 1 |
| Weizman, R | 1 |
| Weizman, A | 1 |
3 trials available for betahistine and Body Weight
| Article | Year |
|---|---|
Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Betahistine; Body Mass Index; Body Weight; Child; Clozapine | 2018 |
Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety; Betahistine; Body Weight; Depression; Health St | 2010 |
The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Betahistine; Body Mass Index; Body Weight; Histamine A | 2005 |
1 other study available for betahistine and Body Weight
| Article | Year |
|---|---|
Crosstalk of hypothalamic chemerin, histamine, and AMPK in diet-and olanzapine-induced obesity in rats.
Topics: AMP-Activated Protein Kinases; Animals; Arcuate Nucleus of Hypothalamus; Betahistine; Body Weight; C | 2021 |